Literature DB >> 34605855

Biallelic variants in SLC38A3 encoding a glutamine transporter cause epileptic encephalopathy.

Dana Marafi1,2, Jawid M Fatih1, Rauan Kaiyrzhanov3, Matteo P Ferla4,5, Charul Gijavanekar1,6, Aljazi Al-Maraghi7, Ning Liu1,6, Emily Sites8, Hessa S Alsaif9, Mohammad Al-Owain10,11, Mohamed Zakkariah12, Ehab El-Anany12, Ulviyya Guliyeva13, Sughra Guliyeva13, Colette Gaba14, Ateeq Haseeb15, Amal M Alhashem16, Enam Danish17, Vasiliki Karageorgou18, Christian Beetz18, Alaa A Subhi19, Sureni V Mullegama20, Erin Torti20, Monisha Sebastin21,22, Margo Sheck Breilyn21,23, Susan Duberstein24, Mohamed S Abdel-Hamid25, Tadahiro Mitani1, Haowei Du1, Jill A Rosenfeld1,6, Shalini N Jhangiani26, Zeynep Coban Akdemir1,27, Richard A Gibbs1,26, Jenny C Taylor4,5, Khalid A Fakhro7,28,29, Jill V Hunter30,31, Davut Pehlivan1,32,33, Maha S Zaki34, Joseph G Gleeson35, Reza Maroofian3, Henry Houlden3, Jennifer E Posey1, V Reid Sutton1,6,32, Fowzan S Alkuraya9, Sarah H Elsea1,6, James R Lupski1,26,32,36.   

Abstract

The solute carrier (SLC) superfamily encompasses >400 transmembrane transporters involved in the exchange of amino acids, nutrients, ions, metals, neurotransmitters and metabolites across biological membranes. SLCs are highly expressed in the mammalian brain; defects in nearly 100 unique SLC-encoding genes (OMIM: https://www.omim.org) are associated with rare Mendelian disorders including developmental and epileptic encephalopathy and severe neurodevelopmental disorders. Exome sequencing and family-based rare variant analyses on a cohort with neurodevelopmental disorders identified two siblings with developmental and epileptic encephalopathy and a shared deleterious homozygous splicing variant in SLC38A3. The gene encodes SNAT3, a sodium-coupled neutral amino acid transporter and a principal transporter of the amino acids asparagine, histidine, and glutamine, the latter being the precursor for the neurotransmitters GABA and glutamate. Additional subjects with a similar developmental and epileptic encephalopathy phenotype and biallelic predicted-damaging SLC38A3 variants were ascertained through GeneMatcher and collaborations with research and clinical molecular diagnostic laboratories. Untargeted metabolomic analysis was performed to identify novel metabolic biomarkers. Ten individuals from seven unrelated families from six different countries with deleterious biallelic variants in SLC38A3 were identified. Global developmental delay, intellectual disability, hypotonia, and absent speech were common features while microcephaly, epilepsy, and visual impairment were present in the majority. Epilepsy was drug-resistant in half. Metabolomic analysis revealed perturbations of glutamate, histidine, and nitrogen metabolism in plasma, urine, and CSF of selected subjects, potentially representing biomarkers of disease. Our data support the contention that SLC38A3 is a novel disease gene for developmental and epileptic encephalopathy and illuminate the likely pathophysiology of the disease as perturbations in glutamine homeostasis.
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  SLC38A3; biallelic; glutamate transporter; glutamate/GABA-glutamine cycle

Mesh:

Substances:

Year:  2022        PMID: 34605855      PMCID: PMC9050560          DOI: 10.1093/brain/awab369

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   15.255


  58 in total

1.  OPM: orientations of proteins in membranes database.

Authors:  Mikhail A Lomize; Andrei L Lomize; Irina D Pogozheva; Henry I Mosberg
Journal:  Bioinformatics       Date:  2006-01-05       Impact factor: 6.937

2.  Identification of a Loss-of-Function Mutation in the Context of Glutaminase Deficiency and Neonatal Epileptic Encephalopathy.

Authors:  Lynne Rumping; Benjamin Büttner; Oliver Maier; Holger Rehmann; Maarten Lequin; Jan-Ulrich Schlump; Bernhard Schmitt; Birgit Schiebergen-Bronkhorst; Hubertus C M T Prinsen; Michele Losa; Ralph Fingerhut; Johannes R Lemke; Fried J T Zwartkruis; Roderick H J Houwen; Judith J M Jans; Nanda M Verhoeven-Duif; Peter M van Hasselt; Rami Jamra
Journal:  JAMA Neurol       Date:  2019-03-01       Impact factor: 18.302

3.  Evidence for cortical dysfunction in autism: a proton magnetic resonance spectroscopic imaging study.

Authors:  Timothy J DeVito; Dick J Drost; Richard W J Neufeld; Nagalingam Rajakumar; William Pavlosky; Peter Williamson; Rob Nicolson
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

4.  Analyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle.

Authors:  Matthew N Bainbridge; Erin Cooney; Marcus Miller; Adam D Kennedy; Jacob E Wulff; Taraka Donti; Shalini N Jhangiani; Richard A Gibbs; Sarah H Elsea; Brenda E Porter; Brett H Graham
Journal:  Mol Genet Metab       Date:  2017-06-24       Impact factor: 4.797

5.  Identification of a pathogenic PMP2 variant in a multi-generational family with CMT type 1: Clinical gene panels versus genome-wide approaches to molecular diagnosis.

Authors:  Jaya Punetha; Loren Mackay-Loder; Tamar Harel; Zeynep Coban-Akdemir; Shalini N Jhangiani; Richard A Gibbs; Ian Lee; Deborah Terespolsky; James R Lupski; Jennifer E Posey
Journal:  Mol Genet Metab       Date:  2018-08-24       Impact factor: 4.797

6.  Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism.

Authors:  Marcus J Miller; Adam D Kennedy; Andrea D Eckhart; Lindsay C Burrage; Jacob E Wulff; Luke A D Miller; Michael V Milburn; John A Ryals; Arthur L Beaudet; Qin Sun; V Reid Sutton; Sarah H Elsea
Journal:  J Inherit Metab Dis       Date:  2015-04-15       Impact factor: 4.982

7.  2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.

Authors:  Adam D Kennedy; Kirk L Pappan; Taraka Donti; Mauricio R Delgado; Marwan Shinawi; Toni S Pearson; Seema R Lalani; William E Craigen; V Reid Sutton; Anne M Evans; Qin Sun; Lisa T Emrick; Sarah H Elsea
Journal:  Front Neurosci       Date:  2019-05-08       Impact factor: 4.677

Review 8.  The genetic landscape of the epileptic encephalopathies of infancy and childhood.

Authors:  Amy McTague; Katherine B Howell; J Helen Cross; Manju A Kurian; Ingrid E Scheffer
Journal:  Lancet Neurol       Date:  2015-11-17       Impact factor: 44.182

9.  Biochemical phenotyping unravels novel metabolic abnormalities and potential biomarkers associated with treatment of GLUT1 deficiency with ketogenic diet.

Authors:  Gerarda Cappuccio; Michele Pinelli; Marianna Alagia; Taraka Donti; Debra-Lynn Day-Salvatore; Pierangelo Veggiotti; Valentina De Giorgis; Simona Lunghi; Maria Stella Vari; Pasquale Striano; Nicola Brunetti-Pierri; Adam D Kennedy; Sarah H Elsea
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240

10.  Michelanglo: sculpting protein views on web pages without coding.

Authors:  Matteo P Ferla; Alistair T Pagnamenta; David Damerell; Jenny C Taylor; Brian D Marsden
Journal:  Bioinformatics       Date:  2020-02-15       Impact factor: 6.937

View more
  3 in total

Review 1.  Harnessing Metabolomics to Advance Epilepsy Research.

Authors:  Tore Eid
Journal:  Epilepsy Curr       Date:  2022-02-17       Impact factor: 7.500

Review 2.  Cerebral Cavernous Malformation: Immune and Inflammatory Perspectives.

Authors:  Tianqi Tu; Zhenghong Peng; Jian Ren; Hongqi Zhang
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

3.  Impact of Inhibition of Glutamine and Alanine Transport on Cerebellar Glial and Neuronal Metabolism.

Authors:  Abhijit Das; Gregory Gauthier-Coles; Stefan Bröer; Caroline D Rae
Journal:  Biomolecules       Date:  2022-08-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.